%D8%AA%D8%A7%D8%B2%D9%88%D8%A8%D8%A7%D9%83%D8%AA%D8%A7%D9%85TazobactamTazobactam%D8%AA%D8%A7%D8%B2%D9%88%D8%A8%D8%A7%DA%A9%D8%AA%D8%A7%D9%85TatsobaktaamiTazobactamTazobakt%C3%A1mTazobactam%E3%82%BF%E3%82%BE%E3%83%90%E3%82%AF%E3%82%BF%E3%83%A0TazobactamTazobaktamTazobactam%D0%A2%D0%B0%D0%B7%D0%BE%D0%B1%D0%B0%D0%BA%D1%82%D0%B0%D0%BCTazobaktamTazobaktam%E0%B8%97%E0%B8%B2%E0%B9%82%E0%B8%8B%E0%B9%81%E0%B8%9A%E0%B8%84%E0%B9%81%E0%B8%95%E0%B8%A1%D0%A2%D0%B0%D0%B7%D0%BE%D0%B1%D0%B0%D0%BA%D1%82%D0%B0%D0%BCQ423376
about
Antimicrobial PK in Infants With Suspected or Confirmed InfectionStudy Evaluation Tazocin InterventionAntibiotic Safety (SCAMP)Safety and Efficacy of Vancomycin Plus Beta-lactamsComparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver DonorsPopulation Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive CarePharmacokinetics of Piperacillin and Tazobactam in Critically Ill PatientsSafety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract InfectionsPrevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell CountComparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-TazobactamClinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas InfectionsMK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas AeruginosaStudy of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsImipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)Ceftolozane Tazobactam Pharmacokinetics in Infected Critically Ill Patients With an Indwelling External Ventricular DrainCeftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical PatientsMonitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical PatientsEfficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
P4844
Rapid-onset piperacillin-tazobactam induced thrombocytopenia.Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Do formulation differences between the reference listed drug and generic piperacillin-tazobactam impact reconstitution?Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.Piperacillin/tazobactam-induced neurotoxicity in a hemodialysis patient: a case report
P921
Q61917969-C629E7DD-EC87-4B89-B934-39485F469D98Q61918261-6E19C1EE-37B1-4A5E-A863-0ECA1FCD40B5Q61969725-E9C9D29B-5EC0-4AB0-8B26-E83ACB730D90Q62030818-9D130AAB-3CD6-45B7-AD36-C3262366E11EQ62031780-A5645EB7-A1DA-434B-9F29-FD58A6A598B3Q62034245-FAAD13BA-84EF-4CE0-9899-E1C2E2EA9602Q62035278-4C18226B-D80E-45A4-8D24-6B874A30BAE7Q62054422-FA759478-F9EC-47A0-949D-81445C10FD07Q62110373-9DFDF75E-AE5E-4EE5-BF30-4B658841B4FAQ62809434-5A43B715-F507-43B5-93B2-69967DB3A72AQ62820932-9BFC4FC7-F7AC-481C-A203-10B097B56AD6Q63012540-7E3B46F4-87EE-4A52-A50E-FEAACF6B4FF0Q63315612-CEA63AAC-9E9E-4F83-B075-9863CE5B7898Q63395045-D2A3984A-B079-4391-AB12-0BD27F8B8144Q63400950-4A8F5398-9C22-4FE3-ACE2-EC0A6369704CQ63571684-5BA50666-2ACF-4723-A25B-B1401F27685EQ63572132-19262C26-F68F-4E65-96F3-2D0457DD275DQ63587447-D267BD6D-C18F-40E7-ADF2-9981A2E50E86Q63598327-4F0EDA05-3040-468C-8193-28E249101664Q86252385-350D1B86-962C-4EDF-A4EA-726D8B7B5567Q86252426-B57D8831-2F4C-4017-8D16-0570D2ED1497Q86300828-8852A222-B89F-4791-94A9-5312DEB4EB3FQ87078540-A3BA9786-ED9F-4D90-8411-DDD4933644D7Q92274074-1CB3B115-5C5D-4E87-A4AB-A919B320F764Q94934483-1BC400EF-0A10-476A-9954-8458906C660C
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tatsobaktaami
@fi
Tazobactam
@de
Tazobactam
@it
Tazobactam
@nl
Tazobactam
@ro
Tazobactam
@vi
Tazobaktam
@pl
Tazobaktam
@sh
Tazobaktam
@sr
Tazobaktám
@hu
type
label
Tatsobaktaami
@fi
Tazobactam
@de
Tazobactam
@it
Tazobactam
@nl
Tazobactam
@ro
Tazobactam
@vi
Tazobaktam
@pl
Tazobaktam
@sh
Tazobaktam
@sr
Tazobaktám
@hu
altLabel
89786-04-9
@fr
C10H12N4O5S
@fr
C10H12N4O5S1
@it
CL-298741
@ar
CL-298741
@en
Tazobactam
@ar
Tazobactam
@en
YTR-830H
@en
tazobactam
@hu
التازوباكتام
@ar
prefLabel
Tatsobaktaami
@fi
Tazobactam
@de
Tazobactam
@it
Tazobactam
@nl
Tazobactam
@ro
Tazobactam
@vi
Tazobaktam
@pl
Tazobaktam
@sh
Tazobaktam
@sr
Tazobaktám
@hu
P527
P486
P592
P6366
P646
P661
P662
P683
P1579
P2017
C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
P2067
300.052841
P2275
tazobactam
@en
P231
89786-04-9